Chimera Investment vs Fennec Pharmaceuticals Which Is Superior?

Chimera Investment Corporation (CIM) and Fennec Pharmaceuticals Inc. (FENC) are two companies operating in distinct sectors of the financial market. CIM specializes in investing in residential mortgage-backed securities, while FENC focuses on developing pharmaceutical drugs for the treatment of rare cancers. Both companies offer investors different opportunities for growth and diversification in their portfolios. By analyzing their financial performance, market trends, and future outlook, investors can make informed decisions on whether to invest in CIM or FENC stocks.

Chimera Investment or Fennec Pharmaceuticals?

When comparing Chimera Investment and Fennec Pharmaceuticals, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Chimera Investment and Fennec Pharmaceuticals.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Chimera Investment has a dividend yield of 9.22%, while Fennec Pharmaceuticals has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Chimera Investment reports a 5-year dividend growth of -18.94% year and a payout ratio of 63.59%. On the other hand, Fennec Pharmaceuticals reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Chimera Investment P/E ratio at 3.43 and Fennec Pharmaceuticals's P/E ratio at -138.67. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Chimera Investment P/B ratio is 0.44 while Fennec Pharmaceuticals's P/B ratio is -32.34.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Chimera Investment has seen a 5-year revenue growth of 0.22%, while Fennec Pharmaceuticals's is 0.00%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Chimera Investment's ROE at 13.35% and Fennec Pharmaceuticals's ROE at 31.99%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $14.89 for Chimera Investment and $5.92 for Fennec Pharmaceuticals. Over the past year, Chimera Investment's prices ranged from $11.29 to $16.89, with a yearly change of 49.60%. Fennec Pharmaceuticals's prices fluctuated between $3.96 and $11.92, with a yearly change of 201.01%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.